17 completed, 3 terminated, 3 unknown, 1 active not recruiting. 25 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 17, Terminated 3, Unknown 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 9 | Completed 5, Unknown 2, Terminated 1, Withdrawn 1 |
Follow Fecal Incontinence: new trials by email Literature Review of Fecal Incontinence trials Research Report on Fecal Incontinence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Implantation of BioSphincter TM for Treatment of Severe Passive Fecal Incontinence Bioengineered Internal Anal Sphincter - Fecal Incontinence | Phase 1 | Active not recruiting | Cellf Bio LLC | 10 | 2022-11-02 | 2025-04-09 |
| Effects of Single Dose Tadalafil on Urethral and Anal Closure Function Tadalafil 40 MG, Placebo - Urinary Incontinence,Stress, Fecal Incontinence | Phase 1 | Completed | University Hospital Bispebjerg and Frederiksberg | 24 | 2021-08-01 | 2022-04-06 |
| Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women fecal microbial transplantation (FMT) - Fecal Incontinence | Phase 1 / Phase 2 | Terminated | University of Pennsylvania | 10 | 2021-01-14 | 2024-06-12 |
| Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Citalopram 40mg, Reboxetine 8 mg, Placebo oral tablet - Stress Urinary Incontinence, Fecal Incontinence | Phase 1 | Completed | University Hospital Bispebjerg and Frederiksberg | 24 | 2019-09-17 | 2021-06-09 |
| Intra-anal Oxymetazoline in Healthy Adult Volunteers Oxymetazoline - Fecal Incontinence | Phase 1 | Unknown | RDD Pharma Ltd | 40 | 2018-08-20 | 2022-08-02 |
| Does Single Dose Imipramine Affect the Opening Pressure of the Urethral and Anal Sphincter? Placebo Oral Tablet, Imipramine Hydrochloride 25 MG - Urinary Incontinence, Stress, Fecal Incontinence | Phase 1 | Completed | Jonatan Kornholt | 16 | 2017-05-16 | 2021-02-12 |
| Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study ALLO-ASC injection, Placebo - Fecal Incontinence | Phase 1 | Completed | Yonsei University | 21 | 2014-12-01 | 2018-08-13 |
| The Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients Oxymetazoline gel, Placebo gel - Fecal Incontinence, Spinal Cord Injury | Phase 1 / Phase 2 | Completed | RDD Pharma Ltd | 19 | 2014-11-01 | 2015-07-28 |
| Endoscopically Assisted Colostomy With Colopexy for Critically Ill Patients Without General Anesthesia or Laparotomy ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY - Colonic Neoplasms, Rectal Neoplasms | Phase 1 | Completed | University of Sao Paulo | 5 | 2014-02-01 | 2014-12-04 |
| Stem Cells Therapy for Fecal Incontinence in Children After Posterior Sagittal Ano-rectoplasty Stem Cells Injection Technique, Stem Cell Isolation - Fecal Incontinence | Phase 1 / Phase 2 | Unknown | Al-Azhar University | 50 | 2013-10-01 | 2014-06-11 |
| Autologous Cell Therapy for Treatment of Fecal Incontinence Iltamiocel - Fecal Incontinence | Phase 1 / Phase 2 | Completed | Cook MyoSite | 53 | 2013-03-28 | 2024-02-16 |
| Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence Urgent(R) PC Neuromodulation System - Fecal Incontinence | Phase 1 | Terminated | Uroplasty, Inc | 30 | 2012-08-01 | 2015-10-29 |
| A Double Blinded Study to Examine the Effect of Alpha Agonist Ointment on Fecal Incontinence in Patients With Idiopathic Fecal Incontinence alpha agonist ointment, Placebo - Idiopathic Fecal Incontinence | Phase 1 / Phase 2 | Withdrawn | RDD Pharma Ltd | 2011-08-01 | 2013-12-12 | |
| An Study to Examine the Effect of Coated Suppositories on Anal Pressure in Healthy Subjects coated suppository - Fecal Incontinence | Phase 1 / Phase 2 | Completed | RDD Pharma Ltd | 6 | 2011-08-01 | 2011-08-23 |
| Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence NRL001, Placebo control - Fecal Incontinence | Phase 1 | Completed | Norgine | 14 | 2010-08-01 | 2012-11-05 |
| Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects NRL001, Placebo - Fecal Incontinence | Phase 1 | Completed | Norgine | 26 | 2010-04-01 | 2010-12-24 |
| Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days NRL001, Placebo - Fecal Incontinence | Phase 1 | Completed | Norgine | 48 | 2010-03-01 | 2010-12-24 |
| Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001. NRL001 - Fecal Incontinence | Phase 1 | Completed | Norgine | 36 | 2009-02-01 | 2009-12-23 |
| Pilot Study of NASHA/Dx Gel for Fecal Incontinence Solesta (Nasha/Dx) - Fecal Incontinence | Phase 1 / Phase 2 | Unknown | Uppsala University Hospital | 16 | 2009-01-01 | 2009-09-03 |
| Evaluation of Outcomes of Restoring Pelvic Floor Support With TOPAS in Women With Moderate Fecal Incontinence Symptoms TOPAS - Fecal Incontinence | Phase 1 / Phase 2 | Completed | ASTORA Women's Health | 29 | 2007-09-01 | 2016-05-23 |
Showing 20 of 25. Sign in to see all of them.
Urinary Incontinence, Stress (3) · Colonic Neoplasms (1) · Encopresis (1) · Gastrointestinal Diseases (1) · Intestinal Diseases (1) · Patient Satisfaction (1) · Rectal Diseases (1) · Rectal Neoplasms (1) · Spinal Cord Injuries (1) · Urinary Incontinence (1)
Digestive System Diseases (25) · Gastrointestinal Diseases (24) · Intestinal Diseases (24) · Rectal Diseases (24) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Lower Urinary Tract Symptoms (4) · Male Urogenital Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Urination Disorders (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Urological Manifestations (4) · Urinary Incontinence (3)
dextranomer-hyaluronic acid copolymer (2) · Citalopram (1) · Fibrin Tissue Adhesive (1) · Imipramine (1) · Oxymetazoline (1) · Reboxetine (1) · Saline Solution (1) · Tadalafil (1)
Norgine (6) · RDD Pharma Ltd (4) · University Hospital Bispebjerg and Frederiksberg (2) · Uppsala University Hospital (2) · ASTORA Women's Health (1) · Al-Azhar University (1) · Anterogen Co., Ltd. (1) · Cellf Bio LLC (1) · Cook MyoSite (1) · Jonatan Kornholt (1) · University Hospital of North Norway (1) · University of Pennsylvania (1) · University of Sao Paulo (1) · Uroplasty, Inc (1) · Yonsei University (1)
United Kingdom (6) · United States (5) · Denmark (3) · Israel (2) · South Korea (2) · Sweden (2) · Brazil (1) · Bulgaria (1) · Canada (1) · Egypt (1) · Hungary (1) · Norway (1)
David Bell, MRCGP MFPM (2) · Abdel-Wahab El-Okby, MD (1) · Anders Mellgren, MD, PhD (1) · Anthony Atala, MD (1) · Barthold Vonen, M.D., Ph.D. (1) · Hala Gabr, MD (1) · Hans Gruss, MD PhD (1) · Jaime Bohl, MD (1) · Jesper Sonne, DMSc (1) · John H Scholefield (1) · John H Scholefield, MD (1) · Jonatan Kornholt, MD (1) · Jonathan A Simpson, MD (1) · Leonardo A Bustamante, MD (1)
PMID 10496568, PMID 12576903, PMID 1929133, PMID 19581853, PMID 24499492, PMID 24499494, PMID 24499495, PMID 24763157, PMID 26888731, PMID 37144409, PMID 38456894, PMID 39076155, PMID 39167201
2009 (2), 2019 (1)